{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:13:34Z","timestamp":1785726814625,"version":"3.56.0"},"reference-count":16,"publisher":"Societas Neurologica Japonica","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rinsho Shinkeigaku"],"published-print":{"date-parts":[[2008]]},"DOI":"10.5692\/clinicalneurol.48.486","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T10:47:17Z","timestamp":1307098037000},"page":"486-491","source":"Crossref","is-referenced-by-count":1,"title":["Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline"],"prefix":"10.5692","volume":"48","author":[{"given":"Takashi","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Neurology, Sendai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sendai Medical Center"},{"name":"Department of Neurology, Touhoku University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Onoue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Sendai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetuya","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Sendai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Oumi","sequence":"additional","affiliation":[{"name":"Department of Cardiosurgery, Sendai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Onodera","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sendai Medical Center"},{"name":"Department of Neurology, Matsuda Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3663","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Grosset KA, Grosset DG: Pergolide in Parkinson's disease: time for a change? Lancet 2004; 5: 1907-1908","DOI":"10.1016\/S0140-6736(04)16369-1"},{"key":"2","first-page":"1179","volume":"10","year":"2004","unstructured":"2) Van Camp G, Flamez A, Cosyns B, et al: Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 10: 1179-1183","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"3","first-page":"859","volume":"23","year":"2003","unstructured":"3) Van Camp G, Flamez A, Cosyns B, et al: Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 23: 859-861","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Delgrange E: Cabergoline and Mitral Regurgitation. N Engl J Med 2006; 26: 420","DOI":"10.1056\/NEJMc053329"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Pinero A, Marcos-Alberca P, Fortes J: Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005; 3: 1976-1977","DOI":"10.1056\/NEJM200511033531822"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Chaudhuri KR, Dhawan V, Basu S, et al: Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord 2004; 19: 1522-1523","DOI":"10.1002\/mds.20330"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Horvath J, Fross RD, Kleiner-Fisman G, et al: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656-662","DOI":"10.1002\/mds.20201"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Pinero A, Marcos-Alberca P, Fortes J: Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005; 3: 1976-1977","DOI":"10.1056\/NEJM200511033531822"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Müller T, Fritze J: Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neurophamacol 2003; 26: 109-111","DOI":"10.1097\/00002826-200305000-00001"},{"key":"10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","volume":"63","year":"2004","unstructured":"11) Baseman DG, O'Suilleabhain PE, Reimold SC, et al: Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63: 301-304","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12) Zadikoff C, Rochon P, Lang A: Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 2006; 33: 27-33","DOI":"10.1017\/S0317167100004650"},{"key":"12","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","year":"2000","unstructured":"13) Rothman RB, Baumann MH, Savage JE, et al: Evidence for possible involvement of 5-HT (2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-2841","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14) Millan MJ, Maiofiss L, Cussac D, et al: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804","DOI":"10.1124\/jpet.102.039867"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15) Zanettini R, Antonini A, Gatto G, et al: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46","DOI":"10.1056\/NEJMoa054830"},{"key":"15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","volume":"67","year":"2006","unstructured":"16) Yamamoto M, Uesugi T, Nakayama T: Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67: 1225-1229","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17) Antonini A, Poewe W: Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6: 826-829","DOI":"10.1016\/S1474-4422(07)70218-1"}],"container-title":["Rinsho Shinkeigaku"],"original-title":["\u30ab\u30d9\u30eb\u30b4\u30ea\u30f3\u670d\u7528\u4e2d\u306b\u5fc3\u81d3\u5f01\u819c\u75c7\u3092\u5408\u4f75\u3057\u305f\u30d1\u30fc\u30ad\u30f3\u30bd\u30f3\u75c5\u306e2\u4f8b"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/48\/7\/48_7_486\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T07:24:21Z","timestamp":1560237861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/48\/7\/48_7_486\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.5692\/clinicalneurol.48.486","relation":{},"ISSN":["0009-918X","1882-0654"],"issn-type":[{"value":"0009-918X","type":"print"},{"value":"1882-0654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}